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Abstract: 7-Phenyl-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine was 
synthesized by a sequence of reactions starting from 6-phenyl-4,5-dihydropyridazin-3(2H)-




C-NMR and mass spectral data. 
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Nitrogen-containing heterocycles play an important role, not only for life science industry but also 
in many other industrial fields related to special and fine chemistry. The interesting pharmacological 
activity displayed by pyridazine derivatives has been demonstrated in recent years not only by the 
growing number of papers and patents describing them but also by the development of several 
pyridazine-based drugs and pharmacological tools [1,2]. Pyridazines are important biologically active 
scaffolds, possessing antihypertensive [3], cardiotonic [4], anti-inflammatory [5], antidepressant [6], 
antibacterial [7], antiaggregative [8], anticancer [9], nephrotopic [10], antithrombic [11], diuretic [12] 
and anti-HIV [13] activities. The current work describes the synthesis of 7-phenyl-3,4,8,9-tetrahydro-
2H-pyridazino[1,6-a][1,3,5]triazin-2-imine 3. 
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The purity of the compounds was checked by single-spot TLC, and the compound was 
characterized on the basis of spectral data (IR, 
1
H-NMR, mass and elemental analysis). Spectral data 
of the synthesized compound 3 were in full agreement with the proposed structure. The IR spectrum 




 and 1,425 cm
−1
 for NH, CH stretching and the 
C=N functional group, respectively. The singlet at δ 2.17 was due to the NH group. 1H-NMR showed 
triplets at δ 2.63 and 2.96 for the cyclic CH2 groups at position 5 and 4, respectively. The singlet at δ 
5.90 was due to the cyclic CH2 group of the triazin-2-imine ring. The aromatic protons appeared as 
multiplets around δ 7.38 and δ7.73. The imine proton appeared as a singlet at δ 8.50. The structure is 
also supported by elemental analysis data and 
13
C-NMR data. The 
13
C-NMR showed peaks at δ 157.2 
and 158.9 for tertiary carbon (C-7) and the imine moiety (C-9a). The mass spectrum showed a peak at 
m/z 228 for [M+1]
+
 in accordance with the molecular formula C12H13N5. The elemental analysis results 
were within ±0.4% of the theoretical values. The starting material 6-phenyl-4,5-dihydropyridazin-
3(2H)-one 1 was synthesized based on a literature method [14]. 
















1 2 3  
Synthesis of 7-phenyl-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine 3 
To a solution of 6-phenyl-4,5-dihydropyridazine-3(2H)-one (0.001 mol) (1) in methanol (30 mL) 
was added formaldehyde (37–41% aqueous solution) (2.5 mL) and the mixture was refluxed for 6 h. 
After completion of the reaction, methanol was distilled off and the residue was poured into crushed 
ice to separate out the intermediate, 2-(hydroxymethyl)-6-phenyl-4,5-dihydropyridazin-3(2H)-one 2. 
The solid which separated was filtered and crystallized from methanol. A mixture of  
2-(hydroxymethyl)-6-phenyl-4,5-dihydropyridazin-3(2H)-one 2 (0.001 mol) and guanidine 
hydrochloride (0.001 mol) was heated in an oil bath for 3 h, cooled and triturated with ethanol. The 
whole content was refluxed on a water bath for 8 h. After completion of the reaction, ethanol was 
distilled off and the residue was poured into crushed ice to separate out the title compound 3. The solid 
which separated was filtered and crystallized from ethanol. The purity of compound 3 was checked by 
TLC, using toluene/ethyl acetate/formic acid (5:4:1) as mobile phase and iodine (I2) as visualizing agent.  
Yield: 30%; m.p. 240–242 °C; Rf 0.45; white cyrstalline solid. 
IR (KBr) υmax (cm
−1
): 3,218 (NH), 3,014 (CH), 1,425 (C=N). 
Molbank 2011  M717 (Page 3) 
 
1
H-NMR (300 MHz, CDCl3): δ 2.17 (s, 1H, NH), 2.63 (t, J = 7.8 Hz, 2H, CH2), 2.96 (t, J = 7.8 Hz, 2H, 
CH2), 5.90 (s, 2H, CH2), 7.38–7.52 (m, 3H, Ar-H), 7.58–7.73 (m, 2H, Ar-H), 8.50 (s, 1H, =NH).  
13
C-NMR (75 MHz, CDCl3): δ 23.6, 26.6, 67.7, 87.8, 128.2, 128.8, 131, 136.4, 146.5, 157.2, 158.9 
(C=NH). 





Anal Calc. for C12H13N5: C: 63.42; H: 5.77; N: 30.82. Found: C: 63.38; H: 5.75; N: 30.78. 
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